{"entity":{"id":"iparomlimab-tuvonralimab","kind":"drug","name":"Iparomlimab and tuvonralimab","aka":["PSB205"],"tldr":"QL1706 is Qilu Pharmaceutical's PD-1 plus CTLA-4 antibody mixture, approved in China in 2024 for recurrent or metastatic cervical cancer after platinum chemotherapy.","summary":"Iparomlimab and tuvonralimab (QL1706) uses Qilu's MabPair platform to produce an anti-PD-1 and a short-half-life anti-CTLA-4 antibody in a single manufacturing run. The NMPA approved it in September 2024 for recurrent or metastatic cervical cancer that had failed platinum-based chemotherapy, the first dual checkpoint product approved for this cancer. Phase 3 trials in lung and liver cancers continue.","status":"approved","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov: trials of QL1706","url":"https://clinicaltrials.gov/search?intr=QL1706"}],"tags":["china","nmpa-approved"],"related":[],"cancers":["cervical"],"sections":[],"technologies":["checkpoint-inhibitor","bispecific-antibody"],"targets":["pdl1"],"drugs":[],"companies":["qilu-pharmaceutical"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06789796","nct07447570","nct07446387"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo China deep dive","editedOn":"2026-09-16"},"code":"QL1706","modality":"Bifunctional antibody mixture: anti-PD-1 and anti-CTLA-4","mechanism":"Two antibodies made in one cell line and given as a fixed mixture: a PD-1 blocker with a normal half-life and a CTLA-4 blocker engineered to clear quickly, so the double checkpoint blockade comes with less of the toxicity seen with ipilimumab combinations.","approvals":[{"region":"CN","year":2024,"indication":"Recurrent or metastatic cervical cancer after platinum chemotherapy"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/iparomlimab-tuvonralimab/","neighbours":{"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"}],"technology":[{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"target":[{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/"}],"company":[{"id":"qilu-pharmaceutical","kind":"company","name":"Qilu Pharmaceutical","route":"/companies/qilu-pharmaceutical/"}],"trial":[{"id":"nct07446387","kind":"trial","name":"A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer","route":"/trials/nct07446387/"},{"id":"nct07502014","kind":"trial","name":"A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and Heterogeneous Radiotherapy Versus Fruquintinib as Third-Line and Subsequent-Line","route":"/trials/nct07502014/"},{"id":"nct06789796","kind":"trial","name":"a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy","route":"/trials/nct06789796/"},{"id":"nct07383285","kind":"trial","name":"CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal C","route":"/trials/nct07383285/"},{"id":"nct07005583","kind":"trial","name":"Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent","route":"/trials/nct07005583/"},{"id":"nct07447570","kind":"trial","name":"Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC","route":"/trials/nct07447570/"},{"id":"nct07413601","kind":"trial","name":"Phase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinum Chemotherapy in the Treatment of Secon","route":"/trials/nct07413601/"},{"id":"nct07416058","kind":"trial","name":"PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC","route":"/trials/nct07416058/"},{"id":"nct07636226","kind":"trial","name":"QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer","route":"/trials/nct07636226/"},{"id":"nct06786026","kind":"trial","name":"QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC","route":"/trials/nct06786026/"},{"id":"nct06750861","kind":"trial","name":"QL1706 Plus Chemotherapy With AG Regime as First-line Treatment of Advanced PDAC","route":"/trials/nct06750861/"},{"id":"nct06951997","kind":"trial","name":"QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer","route":"/trials/nct06951997/"},{"id":"nct07110064","kind":"trial","name":"QL1706+Lenvatinib+AG Regimen as First-line Treatment for Advanced Metastatic Pancreatic Cancer","route":"/trials/nct07110064/"},{"id":"nct07509515","kind":"trial","name":"QLC5513 Alone or in Combination With QL1706 in Previously Treated Advanced or Metastatic TNBC.","route":"/trials/nct07509515/"},{"id":"nct07453394","kind":"trial","name":"QLS5132 Combination Therapy in Advanced Solid Tumors","route":"/trials/nct07453394/"},{"id":"nct07116577","kind":"trial","name":"Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC","route":"/trials/nct07116577/"},{"id":"nct07150247","kind":"trial","name":"Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer","route":"/trials/nct07150247/"}]}}